Open Access

Involvement of bradykinin and bradykinin B1 receptor in patients with endometriosis

  • Authors:
    • Xin Meng
    • Ying Li
    • Qingxue Li
    • Jian Yang
    • Mingli An
    • Xinping Fu
    • Shuancheng Zhang
    • Jingwei Chen
  • View Affiliations

  • Published online on: September 1, 2021     https://doi.org/10.3892/etm.2021.10675
  • Article Number: 1240
  • Copyright: © Meng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Endometriosis (EM), a benign aseptic inflammatory disease, is associated with the presence of endometrial foci. Pain, one of its typical symptoms, has been reported as a constant stressor, but the etiology and pathogenesis of EM‑associated pain are unclear. In the present study, eutopic and ectopic endometrium samples from women with EM (n=50) and normal endometrium samples from control subjects (n=20) were collected. Serum levels of prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α) and bradykinin (BK) were measured using commercial ELISA kits. The expression of the BKB1 receptor (BKB1R) protein was evaluated by immunohistochemical staining and western blot assay. The mRNA expression of BKB1R was measured by reverse transcription‑quantitative PCR. The results revealed that there was a substantial increase in the protein and mRNA expression of BKB1R, as well as the release of PGE2, PGF2α and BK in the blood, in the EM group compared with that in the control group. Moreover, PGE2, PGF2α and BK levels were significantly correlated with each other, as well as with the pain intensity of EM. The increased expression levels of BKB1R protein and mRNA were positively correlated with the pain degree of EM. Thus, these data indicated that BK and BKB1R were involved in the pathological onset of EM‑associated pain and that they may play an important role in EM‑related pain by inducing PGE2 and PGF2α. The data indicate a potential new therapeutic target for EM‑related pain.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 22 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Meng X, Li Y, Li Q, Yang J, An M, Fu X, Zhang S and Chen J: Involvement of bradykinin and bradykinin B1 receptor in patients with endometriosis. Exp Ther Med 22: 1240, 2021.
APA
Meng, X., Li, Y., Li, Q., Yang, J., An, M., Fu, X. ... Chen, J. (2021). Involvement of bradykinin and bradykinin B1 receptor in patients with endometriosis. Experimental and Therapeutic Medicine, 22, 1240. https://doi.org/10.3892/etm.2021.10675
MLA
Meng, X., Li, Y., Li, Q., Yang, J., An, M., Fu, X., Zhang, S., Chen, J."Involvement of bradykinin and bradykinin B1 receptor in patients with endometriosis". Experimental and Therapeutic Medicine 22.5 (2021): 1240.
Chicago
Meng, X., Li, Y., Li, Q., Yang, J., An, M., Fu, X., Zhang, S., Chen, J."Involvement of bradykinin and bradykinin B1 receptor in patients with endometriosis". Experimental and Therapeutic Medicine 22, no. 5 (2021): 1240. https://doi.org/10.3892/etm.2021.10675